ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
Financial & Business 
Read more
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
Science & Medicine 
Read more
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
Science & Medicine 
Read more

https://www.sitcancer.org/2022/home

On  Aug 18, 2022 

Read more

Macrophage-directed Therapies Summit

From  Oct 04, 2022  to  Oct 06, 2022 

Read more

Immuno-Oncology Summit

From  Oct 12, 2022  to  Oct 14, 2022 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news